IN2015DN02573A - - Google Patents

Download PDF

Info

Publication number
IN2015DN02573A
IN2015DN02573A IN2573DEN2015A IN2015DN02573A IN 2015DN02573 A IN2015DN02573 A IN 2015DN02573A IN 2573DEN2015 A IN2573DEN2015 A IN 2573DEN2015A IN 2015DN02573 A IN2015DN02573 A IN 2015DN02573A
Authority
IN
India
Prior art keywords
pulmonary fibrosis
compound
present
formula
idiopathic
Prior art date
Application number
Other languages
English (en)
Inventor
Ulf; Nilsson
Hakon; Leffler
Neil; Henderson
Tariq; Sethi
Alison; Mackinnon
Original Assignee
Galecto Biotech Ab
Univ Edinburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA2794066A external-priority patent/CA2794066C/en
Priority claimed from US13/832,672 external-priority patent/US9243021B2/en
Application filed by Galecto Biotech Ab, Univ Edinburgh filed Critical Galecto Biotech Ab
Publication of IN2015DN02573A publication Critical patent/IN2015DN02573A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/005—Sprayers or atomisers specially adapted for therapeutic purposes using ultrasonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0005—Details of inhalators; Constructional features thereof with means for agitating the medicament
    • A61M15/001—Details of inhalators; Constructional features thereof with means for agitating the medicament using ultrasonic means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0085—Inhalators using ultrasonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN2573DEN2015 2012-10-31 2013-10-30 IN2015DN02573A (enExample)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261720641P 2012-10-31 2012-10-31
CA2794066A CA2794066C (en) 2012-10-31 2012-10-31 Galactoside inhibitor of galectins
CA2795753A CA2795753A1 (en) 2012-10-31 2012-11-15 Novel galactoside inhibitor of galectins
US13/832,672 US9243021B2 (en) 2012-10-31 2013-03-15 Galactoside inhibitor of galectins
PCT/EP2013/072691 WO2014067986A1 (en) 2012-10-31 2013-10-30 Galactoside inhibitor of galectin-3 and its use for treating pulmonary fibrosis

Publications (1)

Publication Number Publication Date
IN2015DN02573A true IN2015DN02573A (enExample) 2015-09-11

Family

ID=52686686

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2573DEN2015 IN2015DN02573A (enExample) 2012-10-31 2013-10-30

Country Status (7)

Country Link
EP (2) EP2914269B1 (enExample)
JP (1) JP2015535233A (enExample)
CN (1) CN104755088A (enExample)
CA (1) CA2884802A1 (enExample)
ES (1) ES2817888T3 (enExample)
IN (1) IN2015DN02573A (enExample)
WO (1) WO2014067986A1 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9243021B2 (en) 2012-10-31 2016-01-26 Galecto Biotech Ab Galactoside inhibitor of galectins
EP2620443A1 (en) 2012-01-25 2013-07-31 Galecto Biotech AB Novel galactoside inhibitors of galectins
EP3415522A1 (en) 2014-07-09 2018-12-19 Galecto Biotech AB Novel hybrid galactoside inhibitor of galectins
US10464964B2 (en) 2015-01-16 2019-11-05 Galecto Biotech Ab Galactoside inhibitor of galectins
EP3828191A3 (en) * 2015-01-30 2021-08-18 Galecto Biotech AB Novel galactoside inhibitor of galectins
ES2834644T3 (es) * 2015-05-12 2021-06-18 Galecto Biotech Ab Tratamiento una vez al día de la fibrosis pulmonar
JP6915956B2 (ja) * 2015-05-15 2021-08-11 ガレクト・バイオテック・エイビイ 肺線維症の１日１回の治療
US10799522B2 (en) * 2015-07-27 2020-10-13 Wayne State University Compositions and methods relating to galectin detection
CA3000924A1 (en) * 2015-11-09 2017-05-18 Galecto Biotech Ab Novel galactoside inhibitors of galectins
EP3896075A1 (en) 2015-12-18 2021-10-20 Galecto Biotech AB Polymorphic forms and process
EP3423461A4 (en) * 2016-03-04 2020-03-25 Galectin Sciences, LLC SELENOGALACTOSIDE COMPOUNDS FOR THE PREVENTION AND TREATMENT OF DISEASES ASSOCIATED WITH GALECTIN AND THEIR USE
EP3484903A1 (en) 2016-07-12 2019-05-22 Galecto Biotech AB Alpha-d-galactoside inhibitors of galectins
WO2018011094A1 (en) 2016-07-12 2018-01-18 Galecto Biotech Ab Alpha-d-galactoside inhibitors of galectins
EP3621973A4 (en) * 2017-05-12 2021-10-27 Galectin Sciences, LLC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF DISEASES AND THEIR USE
US11267811B2 (en) 2017-09-27 2022-03-08 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3
US11072626B2 (en) 2017-10-11 2021-07-27 Bristol-Myers Squibb Company Small molecule inhibitors of Galectin-3
WO2019133878A1 (en) 2017-12-29 2019-07-04 Glycomimetics, Inc. Heterobifunctional inhibitors of e-selectin and galectin-3
MX2020007391A (es) 2018-01-10 2020-09-03 Galecto Biotech Ab Nuevo galactosido inhibidor de galectinas.
CA3100381A1 (en) 2018-05-17 2019-11-21 Actuate Therapeutics, Inc. Treatment of idiopathic pulmonary fibrosis with glycogen synthase kinase 3 form beta inhibitors
EP3807290B1 (en) * 2018-06-15 2022-03-30 Bristol-Myers Squibb Company Tetrahydropyran-based thiodisaccharide mimics as galectin-3 inhibitors
CA3102155A1 (en) 2018-06-29 2020-01-02 Glykos Biomedical Oy Conjugates
CA3114055A1 (en) 2018-10-15 2020-04-23 Galecto Biotech Ab Prodrug of galactoside inhibitors of galectins
EP3867260A1 (en) 2018-10-15 2021-08-25 Galecto Biotech AB Galactoside inhibitor of galectins
US11447517B2 (en) 2018-11-21 2022-09-20 Galecto Biotech Ab Galactoside inhibitor of galectins
CN113166122A (zh) 2018-12-06 2021-07-23 百时美施贵宝公司 半乳糖凝集素-3的小分子抑制剂
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
EP3902797A1 (en) 2018-12-27 2021-11-03 GlycoMimetics, Inc. Galectin-3 inhibiting c-glycosides
US12275719B2 (en) 2019-03-26 2025-04-15 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3
US12269819B2 (en) 2019-04-10 2025-04-08 Bristol-Myers Squibb Company Small molecule inhibitors of Galectin-3
US12291547B2 (en) 2019-06-14 2025-05-06 UNIVERSITé LAVAL Synthesis of 3-azido-3-deoxy-D-galactopyranose
CA3144551A1 (en) 2019-06-24 2020-12-30 Galecto Biotech Ab Large scale process of 3,3'-dideoxy-3,3'-bis-[4-(3-fluorophenyl)-1h-1,2,3-triazol-1-yl]-1,1'-sulfanediyl-di-beta-d-galactopyranoside
EP3993870A1 (en) 2019-07-03 2022-05-11 Galecto Biotech AB Novel galactoside inhibitor of galectins
WO2021001538A1 (en) 2019-07-03 2021-01-07 Galecto Biotech Ab Novel galactoside inhibitor of galectins
CA3143078A1 (en) 2019-07-05 2021-01-14 Galecto Biotech Ab Novel galactoside inhibitor of galectins
WO2021028336A1 (en) 2019-08-09 2021-02-18 Idorsia Pharmaceuticals Ltd (hetero)aryl-methyl-thio-beta-d-galactopyranoside derivatives
JP7612663B2 (ja) 2019-08-09 2025-01-14 イドルシア・ファーマシューティカルズ・リミテッド （２－アセタミジル）チオ－ベータ－ｄ－ガラクトピラノシド誘導体
CA3147454A1 (en) 2019-08-15 2021-02-18 Martin Bolli 2-hydroxycycloalkane-1-carbamoyl derivatives
RS65294B1 (sr) 2019-08-29 2024-04-30 Idorsia Pharmaceuticals Ltd Derivati alfa-d-galaktopiranozida
WO2021123506A1 (en) 2019-12-18 2021-06-24 Glykos Biomedical Oy Stabile conjugate
US20230107479A1 (en) * 2020-03-23 2023-04-06 G3 Pharmaceuticals, Inc. Methods and compositions for preventing and treating fibrosis resulting from a coronavirus infection
JP2023519952A (ja) * 2020-03-31 2023-05-15 ガレクト バイオテック エービー １，２，４，６－テトラ－ｏ－アセチル－３－アジド－３－デオキシ－ｄ－ガラクトピラノシドを調製するための大規模方法
JP7705884B2 (ja) 2020-05-05 2025-07-10 ブリストル－マイヤーズ スクイブ カンパニー ガレクチン－３の低分子阻害剤
US12286424B2 (en) 2020-05-11 2025-04-29 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3
KR20230018431A (ko) 2020-05-28 2023-02-07 브리스톨-마이어스 스큅 컴퍼니 갈렉틴-3 억제제
WO2022073969A1 (en) 2020-10-06 2022-04-14 Idorsia Pharmaceuticals Ltd Spiro derivatives of alpha-d-galactopyranosides
US12291520B2 (en) 2020-11-02 2025-05-06 Idorsia Pharmaceuticals Ltd Galectin-3 inhibiting 2-hydroxycycloalkane-1-carbamoyl derivatives
US12304902B2 (en) 2021-02-09 2025-05-20 Idorsia Pharmaceuticals Ltd Hydroxyheterocycloalkane-carbamoyl derivatives
HUE072194T2 (hu) 2021-03-03 2025-10-28 Idorsia Pharmaceuticals Ltd Triazolil-metil-szubsztituált alfa-D-galaktopiranozid származékok
WO2025111704A1 (en) * 2023-12-01 2025-06-05 UNIVERSITé LAVAL Selective inhibitors of galectin-3

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0170715B1 (de) 1984-08-09 1988-04-13 Inge Brugger Zerstäubervorrichtung
US5152456A (en) 1989-12-12 1992-10-06 Bespak, Plc Dispensing apparatus having a perforate outlet member and a vibrating device
GB9027234D0 (en) 1990-12-15 1991-02-06 Harris Pharma Ltd An inhalation device
CA2112674C (en) 1991-07-02 2005-10-04 John S. Patton Method and device for delivering aerosolized medicaments
EA001237B1 (ru) 1996-01-03 2000-12-25 Глаксо Груп Лимитед Ингаляционное устройство
DE19726110C2 (de) 1997-06-20 1999-07-22 Draegerwerk Ag Aerosolgenerator für Beatmungssysteme
US6962151B1 (en) 1999-11-05 2005-11-08 Pari GmbH Spezialisten für effektive Inhalation Inhalation nebulizer
DE10102846B4 (de) 2001-01-23 2012-04-12 Pari Pharma Gmbh Aerosolgenerator
EP1304130B1 (de) 2001-10-18 2004-06-23 PARI GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung
AU2002343094A1 (en) * 2001-11-26 2003-06-10 Arachnova Therapeutics Ltd. Use of ppar activators for the treatment of pulmonary fibrosis
EP1386672B1 (en) 2002-08-02 2010-04-07 PARI Pharma GmbH Fluid droplet production apparatus
DE10250625A1 (de) 2002-10-30 2004-05-19 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung
DE10257381B4 (de) 2002-12-09 2006-09-14 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung
SE0401301D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel 3-triazolyl-galactoside inhibitors of galectins
SE0401300D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel Galactoside Inhibitors of Galectins
WO2006009209A1 (ja) * 2004-07-22 2006-01-26 Kaken Pharmaceutical Co., Ltd. 慢性炎症性肺疾患を予防もしくは治療する薬剤
WO2010126435A1 (en) 2009-04-28 2010-11-04 Forskarpatent I Syd Ab Novel galactoside inhibitors of galectins
DE102009026636B4 (de) 2009-06-02 2011-04-14 Pari Pharma Gmbh Verfahren zum Verschweißen einer Membran mit einem Träger bei der Herstellung eines Membranverneblers
JP6031510B2 (ja) * 2011-04-12 2016-11-24 モイライ マトリックス インコーポレイテッド 異常な線維芽細胞増殖及び細胞外マトリックスの沈着を特徴とする疾患、症状又はプロセスを予防又は治療する組成物及び方法

Also Published As

Publication number Publication date
ES2817888T3 (es) 2021-04-08
CN104755088A (zh) 2015-07-01
EP2914269B1 (en) 2020-07-29
JP2015535233A (ja) 2015-12-10
WO2014067986A8 (en) 2016-04-14
EP3278805A1 (en) 2018-02-07
CA2884802A1 (en) 2014-05-08
EP2914269A1 (en) 2015-09-09
WO2014067986A1 (en) 2014-05-08

Similar Documents

Publication Publication Date Title
IN2015DN02573A (enExample)
NZ708501A (en) Treatment of pulmonary disease
WO2014028589A3 (en) 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
EA201491672A1 (ru) Гетероциклильные соединения как ингибиторы mek
MY176814A (en) Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
MX368263B (es) Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de fibrosis quistica.
NZ704662A (en) Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
EA201491149A1 (ru) Пиразолопиридиновые производные, способы их получения и их терапевтическое применение
MX375872B (es) Procedimiento de preparacion de 5-fluoro-1h-pirazolopiridinas sustituidas.
TN2014000095A1 (en) Pharmaceutical compositions
MX2015007916A (es) Peri-carbinoles.
MX2015008187A (es) Inhibidores de alk deuterados.
PH12014500990A1 (en) Methods for treating gout flares
MX2013008340A (es) Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer.
WO2013117503A3 (en) Pi3k inhibitors for treating fibrotic diseases
MX347541B (es) Analogos de acido sialico.
PH12014502065A1 (en) Vesicular formulations
PH12015500061A1 (en) Method for preparing substituted triazolopyridines
PH12015502703A1 (en) Pharmaceutical compositions
NZ715554A (en) Method of treating hypertrophic cardiomyopathy
NZ629475A (en) Pharmaceutical composition comprising benzyl alcohol for the treatment of migraines
MX2015007460A (es) Agentes para el tratamiento del dolor y usos de los mismos.
TN2014000227A1 (en) Method for producing substituted 5-fluoro-1h-pyrazolopyridines
TN2013000023A1 (en) Panthenyl docosahexaeneoate and its use for treating and preventing cardiovascular diseases